Objective: The management of diabetes mellitus requires a precise interpretation of blood glucose (BG) data by patients and providers and is increasingly associated with a need for medical technologies that aid in achieving patient-specific outcomes while making the process convenient. This review aims to summarize the current landscape in diabetes management technology, focusing specifically on devices that assist with pattern management in patients with type 2 diabetes (T2DM) who are on multiple-dose insulin regimens. Data Sources: The authors searched MEDLINE to identify articles from 2007 to 2018 that evaluated technologies for BG pattern management and diabetes monitoring. Additional references were generated through review of identified literature citations. Article selection was based on mutual agreement for inclusion. Data Selection and Data Extraction: Relevant articles were defined as English-language articles, describing technologies that assist with diabetes management in insulin-injecting patients with T2DM. Articles that focused exclusively on type 1 diabetes were excluded. Data Synthesis: The literature search yielded 334 articles, of which 21 were included for synthesis. The current BG monitoring practices emphasize the benefit of the structured self-monitoring of BG approach. Several randomized controlled trials conclude that the available technology aids in comprehensive data collection and facilitates communication between patients and providers. Digitally enabled "smart" devices are valuable tools that may help improve outcomes while providing a flexible, personalized approach. Conclusions: Integration of digital technology with diabetes management allows for accurate collection and analysis of data. Emergence of digital tools promotes a comprehensive, precise, and objective approach to glucose monitoring and encourages patient-provider collaborations.
The management of diabetes mellitus (DM) requires, among other things, an assessment of a series of measurements and interpretation of various sets of data. Blood glucose (BG) monitoring is an integral part of diabetes management, with self-measurement and recording of BG data playing an important role in the decision-making process during therapy monitoring. The value of self-monitoring of blood glucose (SMBG) has been well demonstrated, especially for patients using intensive multiple daily injection (MDI) insulin regimens. 1 According to the American Diabetes Association (ADA) guidelines, the benefit or frequency of SMBG in patients on less-intensive insulin therapy (eg, basal only) or those using oral drug only is less-clearly defined, although more frequent monitoring has generally been associated with lower hemoglobin A 1C (A1C) values. 1 Well-orchestrated, systematic SMBG is nevertheless an important enabler of intensive glycemic control, which has been associated with improved A1C values and lower incidence of microvascular complications in type 2 diabetes (T2DM). 2, 3 Intensive glycemic control is influenced by a variety of factors, including physical activity, diet, stress level, sleep quality, hormones, and environment. 4 According to the ADA guidelines, optimization of the diabetes management requires proper review and interpretation of data by both the patient and provider, taking into account specific patient needs such as BG data, food intake, exercise, and pharmacological therapy (such as routine insulin dose). 1 These factors should determine the SMBG frequency and timing. 1 One study evaluated the efficacy of a 7-point SMBG profile (preprandial and postprandial for each meal, plus bedtime). 5 The profiles were collected on 3 consecutive days and have shown a 0.3 percentage-point reduction in A1C more than in the control group. 5 This is consistent with a well-recognized methodology for diabetes management optimization in insulin users-the pattern management approach-which involves establishing a pattern of glucose response over a 3-to 7-day period and then adjusting insulin, food, or activity to attain target BG levels. 5, 6 Other approaches to pattern management exist, which follow the same general premise but require varying frequency of BG test collection (eg, 3 consecutive days of fasting and premeal glucose readings instead of 7-point profiles). 2, 5 When initiating pattern control, it is especially important to maintain consistency in the above factors for a period of time, until a base insulin dose is established. 6 The analysis of patterns should include identification of potential reasons for an abnormal reading. This should be performed by both patient and provider. Patients should be taught how to use SMBG data to adjust food intake, exercise, or pharmacological therapy to attain specific goals. 1 The need for and frequency of SMBG should be reevaluated at each routine visit to avoid overuse of testing. 1 If the pattern is recurring despite consistency in carbohydrate intake, activity level and routine, an adjustment in insulin dose is usually warranted. 2 Another method for monitoring BG data includes continuous glucose monitoring (CGM), whose benefits have been increasingly documented in patients on multiple-dose insulin regimens, in addition to those on continuous insulin infusions. CGM enables the patient and physician to visualize the typical pattern of glucose throughout the day, including changes following meals, exercise, medications, and in response to changes in treatment regimen. 7 It also allows for evaluation of glycemic variability within and between days as well as assessing for hypoglycemia. 8 Flash glucose monitoring (FGM) has also been evaluated in patients with both type 1 diabetes mellitus (T1DM) and T2DM. This approach allows collecting glucose values similarly to CGM; however, the FGM requires users to "wand" their receiver over the glucose sensor to obtain a reading, whereas CGMs transmit data continuously using Bluetooth. 7 Although CGM/FGM are gaining momentum with respect to Food and Drug Administration (FDA) approval, improved technology, accuracy, and patient convenience, CGM is still associated with high cost and data supporting its use in T2DM are lacking. 9 Although there is no consensus in the literature on how SMBG should be structured to detect BG patterns, clinical studies have demonstrated clinical benefits of pattern management, including improvements in glycemic control and more treatment change recommendations. [8] [9] [10] The results of the STeP study and its follow-up demonstrated that more specific formats are associated with higher rates of correct pattern recognition; however, no specific format was globally adopted in clinical practice. 7 The effectiveness of the pattern management approach is dependent on the accuracy, reliability, and comprehensiveness of data recording and storage.
Current insulin dose determination practice involves the use of formulas established by clinical experience and adopted by major organizations in their guidelines. The ADA recommends a starting dose of 0.1 to 0.2 U/kg/d of basal nighttime insulin added to oral therapy for patients with T2DM. 11 Insulin intensification options include adding a single injection of rapid-acting insulin analog before the largest meal or stopping the basal insulin and initiating a premixed (biphasic) insulin twice daily, usually before breakfast and before dinner. 11 These approaches should be utilized whenever patients are not meeting their A1C targets and/or depending on other patient considerations. Much of the data needed for an accurate assessment and dose determination, such as insulin dose and carbohydrate intake, is available to patients who use insulin pumps but may be relatively inaccessible or inaccurate for patients using pens or syringes to administer their injections. 12 This, together with an ongoing demand for greater patient flexibility, sets the stage for medical technologies that help achieve a personalized, accurate, real-time, datasupported management of diabetes. 13, 14 This review outlines the various technologies currently available or under development that aid in glucose pattern management for patients with T2DM on MDI insulin regimens.
Methodology

Data Sources and Selection
The authors performed a MEDLINE literature search using the following search string: diabetes mellitus AND, ( 
Inclusion Criteria
Relevant articles were defined as those involving technologies that assist with glucose pattern management for patients with T2DM on MDI therapy. For a more complete perspective, review articles that addressed the use of various technologies in pattern management were also included. Excluded studies were those that focused exclusively on T1DM or continuous subcutaneous insulin infusion (CSII). Case reports and conference abstracts were also excluded. Article selection was based on mutual agreement for inclusion among the authors. When applicable, literature search findings were supplemented by downloading and reviewing software applications through Google Play and the Apple App Store, in addition to reviewing device manufacturer websites and user manuals. The authors identified these sources by utilizing web search engines (eg, Google) using individual device brand names and manufacturers.
Study Selection
The literature search yielded 334 potentially-relevant articles. After removal of duplicates, 32 records were screened for eligibility, of which 18 records were excluded because of primary focus on T1DM or CSII. Seven additional records were identified through reference checks, bringing the total number of publications included for synthesis to 21. Publications that described results of clinical trials involving pattern recognition technologies were selected and are summarized in Table 1 . The remaining were review articles.
Characteristics of Identified Sources
The following differences were observed among the included articles: sample size and population, study design, as well as studied technology. The location for all included studies was North America. Three studies fit the design of a randomized controlled trial, and four were systematic reviews or meta-analyses. Two studies used an observational design, and one study was a retrospective analysis. Other study designs included survey (2 articles) and evaluations (2 articles), and one study was a proof-of-principle pilot study. The oldest study was published in 2011, and the most recent in 2018. The sample sizes varied between 11 and 907 participants.
Despite the presence of several sources of variation and heterogeneity between articles, no formal assessment of clinical or statistical heterogeneity was conducted because this review did not include a meta-analysis.
Tools for T2DM Glucose Pattern Analysis
Paper Logbooks
Paper logbooks and diaries are generally regarded as the most commonly used tools for BG pattern analysis; however, not much data are available on the proportion of patients who maintain logbooks. A "typical" diabetes logbook includes daily glucose values, time of testing, carbohydrate intake, insulin dosage, and exercise level or illness. Generally, this is more information than what is captured by most glucose meters; however, diabetes logbooks are not standardized, and the comprehensiveness of information will vary from one version to another.
Furthermore, this method of data capture consists of self-reporting and assumes a degree of accuracy that may not exist in reality. 15 The following factors may lead to errors that render the data analysis ineffective: inaccurate transcription, illegibility, failure to record tests at the correct time or with the correct value, and addition of data. Errors in obtaining and reporting the SMBG results can limit the interpretability of the data and have the potential to result in harmful or ineffective therapeutic interventions. 15 An analysis by Given et al, 15 comparing patient-generated BG diary with meter memory data in patients with T2DM, revealed 3 types of recording errors in patients' diaries: incorrectly recording a value that has been measured, failing to record the measured value (underreporting), and adding a value to the diary that has not been measured (overreporting). 15 Although not all errors are intentional, some, such as addition or alteration of data, may be; these behaviors are driven by a desire to improve the impression of glycemic control or in response to pressure from physicians or family. 15 
BG Meters With Built-in Pattern Management Software
Conventional BG meters contain a memory function that allows patients to provide their clinicians with a timestamped history of their BG levels. Besides recording these values, this information does not necessarily assist with pattern recognition because the values are not automatically analyzed and they are presented sequentially and not in a logbook/graphically. Meter memory reviews may also be time-consuming, complicated, and inconvenient for both patients and providers. 16 Currently, one glucose meter that contains built-in pattern detection technology is available (OneTouch Verio IQ; LifeScan Inc, Milpitas, CA). This device incorporates a high/low pattern recognition functionality directly into the BG meter, which indicates to patients when repeated out-oftarget BG is measured. 17 No other glucose meters were identified that provide pattern recognition technology. In a short, single-arm observational study, 71.3% of patients indicated that they preferred use of a meter with high/low pattern recognition technology over a meter without this option. 17 In this study, patients with higher baseline A1C levels received pattern messages at a greater frequency than those with better glycemic control; however, there were no significant changes in BG levels observed at study end, likely because of the short study duration. 
BG Meter-Accompanied Software/Web Applications
Several available software programs can assist patients and providers with glucose pattern analysis. These software programs are developed by the device manufacturer and allow the glucose meter data to be displayed graphically or in logbook-format, or in a variety of different other ways (eg, modal day, ambulatory glucose profile [AGP], etc). Most commonly used BG meters are accompanied by diabetes management software-this usually requires clinicians to download the data from the BG meter to their computer. Home download capabilities can promote selfmanagement decisions, save time during office appointments, and help communicate with the provider in between appointments for assistance with decision making. 18 In a 12-week, single-arm, observational study, use of a web application with glucose pattern detection resulted in a 0.4% reduction in A1C. 19 In this study, 80% of patients were able to detect out-of-range patterns using the software, and 84% of these patients were able to correct the underlying pattern to get BG back in-range. 19 An overview of available device-accompanied software programs is available in Table 2 . The use of data downloads has been historically associated with the challenge of the devices being designed to work with only proprietary hardware and software. This makes the download process inconvenient and time-consuming. It is even more difficult to integrate data from different devices such as a pump and a meter, or between meters. 20 In recent years, platforms have emerged that allow providers to connect glucose meters, CGM, and insulin pumps and obtain a consolidated report, including Diasend & Glooko and Tidepool. 21, 22 Recently, a universal software report was developed to assist with interpretation of glucose patterns, known as the ambulatory glucose profile (AGP). 23 The AGP was proposed as a nonindustry, standardized visual format for analyzing glucose levels and identifying patterns/trends. It is most commonly used in conjunction with CGM or FGM systems); however, it is also used in conjunction with select BG monitors, specifically Freestyle and Accu-Chek brand meters. 
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Stand-Alone Diabetes Management Software
Ubiquitous, stand-alone diabetes management software and mobile applications are available that can also assist with pattern management. Hundreds of mobile applications are available for tracking both glucose data as well as additional data that are relevant to diabetes management, such as physical activity, exercise, stress, sleep, diet, and medications. Besides assisting with tracking and pattern management, mobile applications can also provide additional functionality, including structured display of data, general diabetes education, reminders, and communication between users and peers, family, and clinicians. 25 In a recent metaanalysis of several studies involving diabetes mobile applications, it was determined that the use of mobile app-based interventions improves A1C by approximately 0.5%, with an even greater effect observed in patients with T2DM. However, when comparing applications with general education modules (eg, with pattern recognition) with applications without, no difference was observed in A1C reduction between the 2 application types. 25 One potential drawback to the use of mobile applications is that most of these applications require manual logging of glucose and insulin data, which does not resolve the burden of decision making and data tracking for patients. 4 For this reason, devices with more passive means of data collection, as well as decision support, are more likely to be successful. 26 
Continuous Glucose Monitors/Flash Glucose Monitors
Real-time CGM use is not routinely recommended for patients with T2DM on insulin therapy; however, professional CGM (P-CGM) and FGM are being increasingly utilized in this population. P-CGM refers to the intermittent use (7-14 days) of a CGM sensor that is blinded to the patient, for retrospective clinician review. P-CGM is a means for clinicians to do a glucose pattern "checkup" without requiring patients to purchase a system for personal use. 27 The current recommendation for accurate or reproducible pattern recognition is to analyze 14 days of CGM data. 27 In one study, use of intermittent P-CGM in patients with T2DM led to improvements in glycemic control over 6 months. 28 Use of P-CGM also identified previously unknown hypoglycemia in 38% of patients in this study. 28 Flash glucose monitoring has also been introduced recently as a lower-cost approach to CGM, more suitable for patients with T2DM. Patients with T2DM using FGM have been shown to monitor BG levels more frequently than those using SMBG. 29 Although use of FGM did not improve A1C over SMBG in patients with T2DM, it has been shown to improve hypoglycemia. 29 Patients with T2DM also report that FGM is discreet and convenient to use, provides a complete glycemic profile over several days with easier interpretation of report, and leads to more productive clinician-patient interactions. 30 
Connected Insulin Pens
Recently, digitally enabled insulin pens have been granted FDA clearance, which can bring some functionality of an insulin pump to pen users by enabling insulin dose data capture and potentially a dose calculator, thus opening a personalized approach to a wider population of patients. There are several examples of devices currently in various stages of development that can capture and track delivered dose of insulin and pair this information with a smart phone app to provide personalized, precise, and objective self-management data ( Table 3) .
The clinical benefits of insulin dose capture insulin pens have yet to be established. Early-generation devices without digital data transmission capabilities failed to demonstrate meaningful improvements in A1C or adherence in clinical studies. 31 More recently, a study involving the Emperra ESYSTA system suggests that this device could lower A1C by 0.9% over 15 months of use. 31 However, this study was observational without a control group; thus, further evidence is needed to validate these findings.
Insulin Dose Advisors
Currently, the establishment and adjustment of insulin dose is made based on the relationship between total carbohydrate intake, anticipated physical activity, and current medications and combined with general clinical guidelines and individual experience. Establishing an insulin bolus dose requires a number of factors to be considered: current glucose level, target postprandial glucose level, insulin-to-carbohydrate ratio, insulin correction factor, carbohydrate content of the planned meal, and the amount of bolus insulin on board. 32 Automated insulin dose calculators can be used to determine basal and prandial insulin doses and have been generally associated with minimizing errors in dose determination because of their ability to track repeated correction doses and review dosing records. Potential risks associated with the use of bolus calculators include poor understanding and compliance as well as administering repeated correction boluses while insulin from other recent boluses is still on board (a problem known as "stacking"). 32 A recent review of 46 smartphone calculators for insulin dose calculation found that the majority of apps provide no protection against, and may actively contribute to, incorrect or inappropriate dose recommendations. 33 FDA-cleared bolus calculators are available by prescription only; they come standard in many insulin pumps, and several software-based insulin dose calculators are available in the United States (Table 4) .
Practical Applications of Emerging Technologies and Implications in Pharmacy Practice
Digitally enabled technology allows systematic documentation, processing, and visualization of BG data, which in turn sets the stage for an integrative, personalized process of diabetes management. 13 The use of CGM in patients with T2DM on MDIs is shown to be beneficial in some studies. A study by Beck et al 34 showed that participants with T2DM on MDI randomized to the CGM arm had significantly greater reduction in A1C levels at week 24 compared with those in the SMBG arm (7.7% vs 8.0%; P = 0.022). 34 In the DIAMOND trial, older adult participants with T1DM and T2DM on MDI therapy were randomized to CGM or SMG (baseline average age 67 ± 5). Participants in the CGM arm had greater reductions in A1C from baseline to 24 weeks compared with the control group (−0.9% ± 0.7% vs −0.5% ± 0.7%; P < 0.001). This study had a high adherence rate, with 97% of patients using CGM ⩾6 days per week for 6 months with a satisfaction score of 4.2 ± 0.4 out of 5 on the CGM Satisfaction Survey. 35 It may be assumed that most older adults will struggle with learning and using diabetes technology at home, but these studies prove otherwise. Approximately 50% of participants enrolled in the study by Beck et al were ⩾60 years old, whereas the DIAMOND trial exclusively enrolled those ⩾60 years old with no difference in hypoglycemia rates between the 2 treatment arms in both studies. Although CGM may not be appropriate for all patients with T2DM on MDIs, it may be a good option for those who experience hypoglycemia unawareness or frequent episodes of hypoglycemia. Special populations such as pediatric patients and the elderly are especially vulnerable to hypoglycemia because of their diminished ability to recognize its signs and symptoms. A small study of 122 participants with T2DM showed that the prevalence of hypoglycemia unawareness was 9.8%, and it increased the risk for severe hypoglycemia by 17-fold. 36 CGMs can be set to provide an alarm to the patient when BG levels are close to hypoglycemic levels, thereby preventing an episode of hypoglycemia from occurring. The ADA recommends that patients who are successfully being treated with CGMs should have continued access to these devices after they turn 65 years old.
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A device that captures insulin dose can also be specifically useful in establishing insulin-to-carbohydrate ratios as well as insulin sensitivity (correction factor). Additionally, patients who are using bolus calculation software would benefit from a pen that tracks administered insulin, which can prevent stacking. 32 Use of these devices in patient care settings will vary based on patient need and health literacy. Patients with T2DM who are controlled with basal insulin alone will likely not need such sophisticated technology, unless they are actively titrating their insulin dose. It may be useful for patients with T2DM who are being treated with MDI. These insulin dose capture technologies can help correlate BG with insulin dose and aid in more precise insulin dose titration. This is especially important in special populations such as pediatric and geriatric patients. There is an increasing number of pediatric patients diagnosed with T2DM, something that was uncommon years before. It is estimated that the incidence of T2DM has increased to 25% to 45% among all youth diagnosed with diabetes. These numbers were only at 1% to 2% in the mid-1990s. 37 Because the average age of onset of T2DM in pediatric patients is 12 to 16 years, the parent of the child may be playing an active role in insulin dose adjustment and assessing glucose control. In these scenarios, insulin dose capture devices and bolus calculators can help ease the burden of dose calculation for the parent. 37, 38 Data from insulin dose capture devices can aid both the patient and provider in making informed and accurate decisions regarding diabetes management and reduce the risk of glucose excursion-related adverse events. It can also enable clinicians to more easily troubleshoot problems encountered with insulin therapy, such as nonadherence, over-and underadministration, and incorrect timing of administration. Recent data collected from 31 patients with a Bluetooth-enabled pen suggests that 100% of patients, regardless of age, deviated from their insulin prescription; 12% of injections were missed or underbolused, 20% were extra or overbolused, and 29% of injections were taken outside of the window of scheduled dosing. 39 Many insulin dose-capture and bolus calculator technologies require the use of a cellular app. A meta-analysis of randomized clinical trials that evaluated the use of diabetes mobile applications in self-management reported a mean reduction of 0.49% in A1C in patients with T2DM (95% Cl = 0.30, 0.68; P = 0.01; I2 = 10%). 40 (I2 is a statistic used in meta-analyses that reflects the degree of heterogeneity among included studies).
Health equity continues to be a problem for minority groups and T2DM patients with low socioeconomic status. African American and Latino patients experience a 50% to 100% higher burden of illness and mortality from diabetes than white Americans. 41 Although minority patient populations may especially benefit from diabetes technologies, their financial barriers may prevent its use. For this reason, the ADA has several advocacy initiatives to improve access to health care and end health disparities among minority communities. 42 Advancement in diabetes technologies provide greater options for patients and their providers in the management of T2DM. As recommended by the ADA, patients using technologies such as CGM will need continuous education and training to ensure patient safety and improve glycemic control. It is important for health care providers to assess patient readiness when recommending the use of technology. 1 Given the overall high cost of diabetes monitoring, there is a need for monitoring practices that are cost-effective. The cost associated with the use of described technology needs to include not only direct costs to patients and providers, but also costs associated with training necessary for the providers and patient education. A recent cost-effectiveness analysis from the DIAMOND trial has shown that CGM was cost-effective when compared with daily use of test strips in T1DM patients using MDI. 43 The financial benefits in T2DM patients are yet to be established.
Limitations
A potential limitation to this review is a relatively small number of randomized clinical trials that evaluate the use of technology in diabetes monitoring. Furthermore, the studies and articles that were included were not formally assessed for clinical or statistical heterogeneity. The search was limited to articles in English, which may have restricted the number of relevant studies that were identified.
Conclusion
A major part of successful diabetes management is being able to accurately capture and interpret the relationship between insulin dose and BG levels. For this reason, technologies that assist with BG pattern recognition as well as emerging insulin dose capture and bolus calculator technologies can play a vital role in facilitating clinical decision making for providers and patients.
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